Patient-Reported Outcome and Quality of Life Data on Maintenance Therapy

Pembrolizumab with platinum-based chemotherapy yielded encouraging progression-free and overall survival outcomes in this patient population.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Data from TROPiCS-04 did not meet the primary end point of overall survival among those with locally advanced or metastatic urothelial cancer.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

TAR-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.

Phase 3 EV-302 results supported the approval, showing a statically significant survival benefit compared with chemotherapy in urothelial carcinoma.